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Hypospadias is one of the most common congenital malformations of the genitourinary tract in males. It is an
incomplete fusion of urethral folds early in fetal development and may be associated with other malformations of
the genital tract. The etiology is poorly understood and may be hormonal, genetic, or environmental, but most
often is idiopathic or multifactorial. Among many possible risk factors identified, of particular importance is low
birth weight, which is defined in various ways in the literature. No mechanism has been identified for the
association of low birth weight and hypospadias, but some authors propose placental insufficiency as a common
inciting factor. Currently, there is no standardized approach for evaluating children with hypospadias in the setting
of intrauterine growth restriction. We reviewed the available published literature on the association of hypospadias
and growth restriction to determine whether it should be considered a separate entity within the category of
disorders of sexual differentiation.
Keywords: Intrauterine growth restriction, Fetal growth restriction, Small for gestational age, Low birth weight,
Placental insufficiency, HypospadiasIntroduction
Hypospadias is a common congenital malformation in
males, occurring in as many as 1 in 125 live male births,
with some variation based on ethnicity [1-3]. Defined as
an abnormal urethral opening on the ventral surface of
the penis, it may be associated with other genitourinary
anomalies such as cryptorchidism. Despite some argu-
ment to the contrary [3-7], many recent studies have
documented an increase in the incidence of hypospadias,
both in the United States [8,9] and worldwide [10-13].
Identifying the cause of hypospadias remains a chal-
lenge for pediatricians, endocrinologists, and urologists,
as the etiology is varied and often idiopathic or multifac-
torial, particularly for isolated hypospadias. Some cases
have a defect in hormonal synthesis, such as in 5-alpha
reductase deficiency [14] or androgen insensitivity syn-
drome [15]. Genetic causes include certain syndromes* Correspondence: minjyec@bcm.edu
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unless otherwise stated.(e.g., Smith-Lemli-Opitz syndrome [16] and others [17]),
abnormalities in sex chromosomes, or mutations in spe-
cific genes involved in sexual differentiation [18-20]. En-
vironmental causes also contribute to the development
of hypospadias. For example, an increase in the use of
pesticides and other endocrine-disrupting chemicals may
contribute to the recent increase in incidence [21-25].
Among other maternal-fetal factors, low birth weight
(LBW) has been associated with hypospadias, although
the mechanism is unclear. Evaluation of this relationship
is complicated by inconsistent definitions for LBW or
intrauterine growth restriction (IUGR) in the literature.
The purpose of this article is to review the association of
LBW or IUGR with hypospadias and to determine if
hypospadias and IUGR should be considered a distinct
entity within disorders of sexual differentiation (DSD)
that would require a different process of diagnostic
evaluation and treatment.Methods
To elucidate the association between IUGR or LBW and
hypospadias, we conducted a review of the availabletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Scholar to answer the following questions:
1. Is growth restriction or LBW associated with
hypospadias independently of other related factors,
including gestational age?
2. In patients with IUGR and hypospadias, are the
diagnostic evaluation and management of the
hypospadias different from those for patients
without IUGR?
We evaluated studies published in English, including
case reports, observational studies, and controlled trials,
that describe the relationship between hypospadias and
LBW, IUGR, or small for gestational age. Search terms
included hypospadias, fetal growth restriction, intrauter-
ine growth restriction, small for gestational age, placen-
tal insufficiency, and low birth weight.
Results
Definitions
Descriptions of growth restriction vary in the literature,
often with definitions based purely on birth weight, size
for gestational age, or prenatal measurements. As a re-
sult, direct comparisons between studies are difficult.
LBW and “small for gestational age (SGA) are both post-
natal diagnoses. LBW refers strictly to birth weight [26],
whereas SGA may refer to abnormal weight or length
for gestational age [27,28]. In contrast, IUGR is primarily
an obstetric diagnosis, as it depends on prenatal mea-
surements. The term applies when the estimated fetal
weight (EFW) is less than expected for gestational age,
usually with the restriction persisting over some period
of time, though a length of time requirement is not
specified in most guidelines [29-31].
There is controversy over the definitions for SGA and
IUGR. Though most authors use a cutoff of less than
10th percentile for gestational age for both SGA and
IUGR, many researchers propose using more stringent
definitions, as most infants who meet the 10th percentile
criterion are constitutionally small and have normal
perinatal outcomes [27,32,33].
Most studies evaluating the association of growth re-
striction with hypospadias use SGA or LBW definitions,
sometimes interchangeably with IUGR. Although IUGR
may lead to the diagnoses of SGA or LBW, the terms are
not interchangeable. An infant may be born SGA without
having had IUGR, or may have had a short period of IUGR
without being SGA. Infants who are SGA may or may not
be LBW, depending on gestational age. Pathologic growth
restriction may be caused by genetic anomalies such as
single gene mutations or chromosomal abnormalities,
infections, placental disease, and maternal factors [34].
Studies have linked true fetal growth restriction to multiplecongenital anomalies (including, but not limited to, hypo-
spadias) [35-39], increased morbidity in the neonatal
period [40], and long-term effects such as neurodevelop-
mental differences [41], short stature, increased risk of
obesity, and metabolic syndrome [42]. Thus, identifying
those infants at greatest risk of morbidity calls for a clear
definition of IUGR.
Is growth restriction or LBW associated with hypospadias
independently of other related factors, including
gestational age?
For decades, epidemiological studies (Table 1) have found
that infants with hypospadias have birth weights lower
than those of infants without hypospadias [2,35,36,43-46],
although the difference in birth weights is not always sta-
tistically significant [47]. Because most studies evaluated
multiple risk factors, the determination of whether LBW
is independently associated with hypospadias or secondary
to another risk factor such as maternal age or gestational
age remains unknown. More recent population-based
studies independently associated birth weight with hypo-
spadias, even after accounting for possible confounders
such as prematurity, multiple gestation, and use of assisted
reproductive technologies [4,13,37,48,49].
Case control and cohort studies also have found asso-
ciations between hypospadias and birth weight. Birth
weights were lower for boys with hypospadias than for
those without hypospadias [50], and hypospadias also
was more common in SGA or LBW infants [51]. These
studies reported no relationship between gestational age
and the frequency of hypospadias.
LBW also is associated with other genital anomalies,
including cryptorchidism and more severe forms of
DSD. A recent analysis of the International Disorders of
Sex Development (I-DSD) registry found that as many
as 23 percent of patients with male DSD also had SGA
[52]. Patients with more severe anomalies, including
hypospadias and undescended testes, have higher rates
of IUGR than those with less severe anomalies, such as
hypospadias and descended testes [53]. Birth weights
and/or lengths are lower in patients with an unknown
cause for DSD than in patients with identified causes for
DSD, suggesting that growth retardation, particularly
early in gestation, may be associated with abnormal tes-
ticular differentiation or DSD [54,55].
Twin studies support the relationship between re-
stricted fetal growth and hypospadias by eliminating
genetic and external environmental factors. In monozy-
gotic twins discordant for hypospadias, the twin with the
lower birth weight more commonly had hypospadias,
and the difference in weight was significant [38,56,57].
This finding suggests that environmental factors specif-
ically associated with the LBW twin, such as decreased
placental blood supply, are involved in the development
Table 1 Summary of epidemiological studies associating hypospadias with low birth weight
Study (year) Dataset location (years) Number of subjects
with hypospadias
Definition Findings Other positive associations
Chen (1971) [43] Children’s Hospital
of Michigan (1961–1967)
50 NA Mean birth weight: hypospadias
2.7 kg, expected 3.3 kg
Parity
p < 0.001
Sweet (1974) [2] Rochester, Minnesota, USA (1940–1970) 113 LBW: <2500 g Presence of LBW in hypospadias 9%
Control 2%
No p value given




Calzolari (1986) [45] Emilia Romagna, Italy (1978–1983) 168 NA Mean birth weight: hypospadias
2.97 kg, Controls 3.39 kg
Mother’s age at menarche,
threatened abortion, use of
progestins in pregnancy,
gestational agep < 0.001
Kallen (1986) [46] Multiple: Denmark, Hungary, Italy,
Mexico, South America, Spain,
Sweden (years vary 1967–1982)
7491 LBW: <2500 g Presence of hypospadias in LBW: Maternal age, parity, gestational
age, twin pregnancy
RR 1.8-2.3 (varied by country)
Khoury (1988) [35] Atlanta, Georgia, USA (1975–1984) 1111 IUGR: <10 percentile birth
weight for gestational age
Presence of IUGR in hypospadias: Not evaluated
RR (95% CI): 2.7 (2.3-3.1)
Stoll (1990) [47] Alsace, France (1979–1987) 176 NA Mean birth weight: hypospadias
3.19 kg, controls 3.3 kg
Placental weight
OR 2.05 (95% CI 0.73-5.74)
Mili (1991) [36] Atlanta, Georgia,
USA (1978–1988)





Riley (1998) [37] Victoria, Australia (1983–1995) 2012 LBW <2500 g Presence of LBW in hypospadias:
RR (95% CI): 2.23 (1.88-2.65)
Akre (1999) [48] Sweden (1983–1993) 1220 NA Presence of LBW in hypospadias:
Adjusted OR (95% CI):
Maternal age, parity, severe
pre-eclampsia, other congenital
malformations
<1500 g: 6.02 (2.51-14.41)
1500-2500 g: 2.57 (1.71-3.85)
Weidner (1999) [49] Denmark (1983–1992) 1345 NA Presence of LBW in hypospadias:






















Table 1 Summary of epidemiological studies associating hypospadias with low birth weight (Continued)
Carmichael (2003) [4] California, USA (1984–1997) 5838 NA Presence of LBW in hypospadias: White ethnicity, maternal
education, maternal age, parity
Adjusted RR (95% CI)
<1500 g: 2.46 (1.65-3.68) to 57.5
(31.8-104) depending on severity
and other anomalies
1500-2499 g: 2.16 (1.73-2.69) to 18.8 (12.4-28.5)
Carlson (2009) [58] Nova Scotia, Canada (1980–2007) 995 NA Birth weight in different severities of hypospadias: Maternal age
Adjusted OR 1.00, 95% CI 0.99-1.00
Ghirri (2009) [59] Italy (2001–2004) 234 SGA: <10 percentile
for gestational age
Prevalence of hypospadias in SGA: None
5.28 per 1000 live births (compared
to 2.56 per 1000 in AGA), p < 0.01
Significance only in moderate-severe
hypospadias
Nordenvall (2014) [13] Sweden (1973–2009) 7974 SGA: <2 SD below mean Presence of SGA in hypospadias: Parental origin, maternal body
mass index, in vitro fertilization,
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risk of hypospadias in twins compared to singletons
when adjusted for weight, although this study did not
compare weights between discordant twins [49].
Despite the evidence supporting the association be-
tween LBW and hypospadias, some debate continues.
Determining causality is difficult due to the nature of
the available studies. In addition, some studies find ei-
ther no correlation between hypospadias and birth
weight after accounting for confounders [58] or that
birth weight was a risk factor only for severe hypospa-
dias [59]. However, the populations in these studies were
smaller than those in the studies that found a broader
association between LBW and hypospadias.
Possible mechanisms
Hypospadias is the result of incomplete fusion or failure of
fusion of the urethral folds during early fetal development.
Two basic phases occur in the development of a male
phenotype. The first phase is testicular development,
which typically is determined by the presence of the Y
chromosome, specifically the SRY gene, although many
other genes also participate in testicular development. The
second phase involves androgen effects through produc-
tion by the testes as well as downstream responses. Defects
in either phase may lead to abnormal sexual differentiation
[60]. Typically, the external genitalia are undifferentiated
until approximately week 8 of gestation, at which time dif-
ferentiation to male external genitalia begins. During this
critical period, human chorionic gonadotropin (HCG) in-
duces masculinization by stimulating the production of
testosterone and dihydrotestosterone (DHT) by the inter-
stitial cells of the fetal testes. Fusion of the urethral folds
usually is complete by approximately week 16 of gestation;
thus, environmental or hormonal disturbances, including
any underlying causes of IUGR, must occur before this
time to cause hypospadias [61]. Although establishing con-
clusively that early IUGR is associated with development of
hypospadias is difficult, one retrospective cohort study did
find a higher rate of hypospadias in infants who were SGA
in all three birth measures (i.e., weight, length, and head
circumference), compared to those considered appropriate
or large for gestational age. The combination of SGA mea-
surements is suggestive of growth restriction early in gesta-
tion [51].
Several studies have associated birth weight and hypo-
spadias to disturbances in the fetal-placental-maternal
unit. In SGA infants, including those with hypospadias,
some researchers have noted an association with maternal
hypertension, oligohydramnios, and preterm birth [62,63].
Placental and fetal weight tend to be lower in hypospa-
dic infants, independent of gestational age [47,62,64,65],
and the severity of hypospadias is increased in SGA
infants [63].Other studies looking more directly at the placenta and
fetal growth suggested placental insufficiency as an incit-
ing factor for both LBW and hypospadias. Histopathologic
examination of placentas of patients with hypospadias and
LBW revealed abnormalities such as low placental weight,
evidence of infarction, calcifications, abnormal cord inser-
tion, and other degenerative changes [57,64].
Based on the associations between LBW or IUGR and
hypospadias, some researchers have hypothesized that
placental insufficiency in the first trimester may cause
inadequate HCG delivery to the fetus, with the resultant
fetal production of testosterone and DHT being inad-
equate to induce complete virilization [51,56,61]. The
timing is critical, as later placental insufficiency might
cause IUGR but not hypospadias, as the fusion of the ur-
ethral folds is complete by week 16. This hypothesis has
been challenged, as some studies have found no differ-
ence in maternal HCG levels before 18 weeks gestation
in patients with hypospadias compared to controls [66]
and higher than normal second-trimester maternal HCG
levels in mothers with placental dysfunction [67]. How-
ever, these studies did not necessarily measure maternal
HCG levels in the period of time when urethral fusion
would be expected to occur. Regardless, normal or high
maternal HCG levels do not guarantee that sufficient
levels are available to the fetus to produce testosterone
and DHT levels adequate for virilization, as the HCG
levels seen by the fetus is dependent on an intact placen-
tal vessel delivery system.
In patients with IUGR and hypospadias, are the diagnostic
evaluation and management of the hypospadias different
from those for patients without IUGR?
We did not identify studies that discussed the diagnostic
evaluation and management of hypospadias specifically
in the setting of IUGR or LBW. Although some genetic
syndromes feature both IUGR and hypospadias (e.g.,
Wolf-Hirschhorn (4p-) syndrome [68] and others), they are
rare, and the evidence is insufficient to suggest that the
evaluation of hypospadias should differ significantly in
IUGR patients compared to normal-weight patients. Evalu-
ation of patients with both IUGR and hypospadias should
include a systematic, evidence-based approach, such as the
algorithm provided in Figure 1, summarized below.
For infants with hypospadias and evidence of IUGR, as-
sessment should begin with evaluation of an underlying
etiology for the growth restriction, including genetic
abnormalities or infection [34], if a cause of poor growth
was not identified prenatally. Karyotype or chromosomal
microarray evaluation would be particularly useful to iden-
tify genetic etiologies of severe hypospadias as well as
IUGR, as patients with sex chromosome abnormalities,
including but not limited to 46 XY/45 XO or 46 XX with
virilization, can present with some degree of DSD [69]. If
Figure 2 Diagram of commonly used classifications of
hypospadias, based on location of urethral meatus. These
categories were described by Boisen [70], Duckett [71], Hadidi [72],
and Smith [73].
Figure 1 Proposed diagnostic algorithm for initial hormonal and genetic testing for etiology of hypospadias in setting of IUGR.
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sider further evaluation for gonadal dysgenesis.
In the evaluation of hypospadias in infants known to be
46 XY, the severity of hypospadias must be considered, as
pathology identified is more often in severe cases. The
classification of hypospadias usually depends on the loca-
tion of the urethral opening (Figure 2) [70-73], as well as
the presence of other genitourinary anomalies such as
cryptorchidism. Some studies have evaluated the hormo-
nal status in patients with hypospadias, with inconsistent
protocols and results. However, evaluation of HCG-
stimulated testosterone and DHT production may be the
most useful in diagnosing an endocrine etiology for hypo-
spadias. Patients with hypospadias may have abnormal
stimulated production of testosterone, especially if other
genitourinary abnormalities are present on exam [74-76].
Increased testosterone-to-DHT ratio suggests 5-alpha
reductase deficiency, whereas decreased testosterone
production may indicate testicular dysgenesis or defects
in steroidogenesis, including 3-beta hydroxysteroid
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ciency. Elevated androgen levels may occur in partial
androgen insensitivity. If dysmorphic features or multiple
congenital anomalies exist, further genetic evaluation may
be indicated for evaluation of known syndromes.
Surgery is the definitive treatment for hypospadias, and
preoperative androgen therapy often helps facilitate the re-
pair, particularly in patients with small penile size, although
its use remains controversial [77]. Preoperative androgen
therapy increases penile length, diameter, or circumference
with minimal and transient side effects [78-83]. Intramuscu-
lar testosterone is the preferred therapy [77,79-81], although
some studies have reported positive outcomes with topical
testosterone and DHT [78,83,84]. The dosages of intramus-
cular testosterone varied, but studies using low-dose testos-
terone enanthate (2 mg/kg or 25 mg) or equivalent doses of
other formulations had beneficial results in penile size simi-
lar to those of studies using higher doses. For patients with
5-alpha reductase deficiency or partial androgen insensitiv-
ity, a higher dose or multiple courses of testosterone ther-
apy may be needed [85]. DHT, if available, may also be
useful in patients with 5-alpha reductase deficiency [86].
Conclusions
Hypospadias is one of the most common congenital
malformations in males, but its etiology remains poorly
understood. LBW or growth restriction, which often is
associated with hypospadias, is one of the risk factors
that researchers have evaluated. The mechanism is un-
known, but placental insufficiency as a possible cause of
both IUGR/LBW and hypospadias should be studied fur-
ther. The current evidence is insufficient to recommend
that patients with IUGR and hypospadias be assessed
and managed differently from patients of normal weight.
Further studies are needed to develop a standardized
algorithm for diagnostic evaluation and management to
minimize cost and patient discomfort and to determine
whether hypospadias in the setting of IUGR should be
considered a separate DSD entity in the future.
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